To the Editor: In the Food and Drug Administration (FDA)-mandated safety trial by Ytterberg et al., patients who were treated with tofacitinib had a higher incidence of cancer than those treated with a tumor necrosis factor (TNF)
No takes yet. Share an insight, caveat, or question.
A 2022 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: